Date de publication: 28 avril 2010
Promoteur – Intermédiaire Financier
Chiesi Farmaceutici SpA
Lieu
Description
The project consists of Chiesi’s research and development activities in Italy and partly (8%) in the UK, oriented towards (i) respiratory diseases, (ii) specific technology platform (nebulised and pulverised dosage forms) and (iii) infant respiratory distress syndrome (IRDS) or neonatal respiratory distress syndrome (NRDS).
Objectifs
Improving the health of European citizens and increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses, while addressing global health issues including emerging epidemics, is one of the key objectives of the FP-7 on research. This research focuses, inter alia, on respiratory diseases including those induced by allergies, as they have a high impact on the quality of life.
Secteur(s)
Montant BEI envisagé (montant approximatif)
Up to EUR 80 million.
Coût total (montant approximatif)
Approximately EUR 170 million.
Aspects environnementaux
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA), therefore, is not required by EU Directive 97/11 amended by Directive 2003/35.
Passation des marchés
The promoter is a private company, not operating in the Utilities sector and therefore not covered by EU Directives on procurement. Procedures followed are in the best interest of the project and satisfactory to the Bank.
Statut
Signé - 20/12/2010
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).